Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release.

The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine, while reducing side effects, and the duration of said side effects when they do happen.

“By continuing to innovate in directions to enhance the patient experience and reducing clinical observation times, we believe our treatments can decrease costs and increase the capacity of medical professionals in this field, which will promote increased access to these important therapeutics for those in need,” said Doug Drysdale, chief executive officer.

Cybin is a biotechnology company working to provide innovations for the burgeoning psychedelics space through development, research and deployment of novel drug delivery systems, novel formulation approaches and treatment regimens.

Patent Filing Highlights:

  • The Company has a provisional patent application including disclosures directed to novel oral dosage forms believed to provide therapeutic advantages in addressing the Company’s target indications over the current art.
  • The patent application is synergistic with other patent applications filed by the Company related to a delivery technology covering various chemically synthesized psychedelic molecules which is expected to provide faster onset times in a similar route to intravenous treatments.
  • The patent application bolsters the Company’s portfolio related to deuterated psychedelic molecules and analogues which are expected to provide greater stability, better potency, more control over duration and greater bioavailability than other forms of these molecules.
  • The patent application disclosures related to faster therapeutic onset, decreased duration, and decreased side effects are anticipated to greatly reduce the clinical costs of administration resulting from reduced clinical observation time.

The patent also includes methods intended to use the compositions to promote not only faster onset and decrease side effects, but also decreased duration of action.

Source: stockwatch.com

Cybin’s up a penny today, trading at a $1.82.

—Joseph Morton

Full disclosure: Cybin is an equity.guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Biotech
Featured Content
Morton
Mushroom Moves
Psychedelics
Shroom Boom
Bioavailability
biotechnology
cybin
CYBN.C
drug delivery systems
patents
pharmaceuticals
psychedelics
tryptamine
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments